Patents by Inventor Paul Beswick
Paul Beswick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240173422Abstract: The present invention relates to drug conjugates comprising at least two polypeptides which are each covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also relates to pharmaceutical compositions comprising said drug conjugates and to the use of said drug conjugates in preventing, suppressing or treating diseases, such as those which may be alleviated by cell death, in particular diseases characterised by defective cell types, proliferative disorders such as cancer and autoimmune disorders such as rheumatoid arthritis.Type: ApplicationFiled: October 15, 2020Publication date: May 30, 2024Inventors: Paul Beswick, Gemma MUDD, Michael RIGBY
-
Publication number: 20240108737Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), particularly the spike protein S1 of SARS-CoV-2. The invention also includes pharmaceutical compositions comprising said polypeptides and to the use of said polypeptides in suppressing or treating a disease or disorder mediated by infection of SARS-CoV-2 or for providing prophylaxis to a subject at risk of infection of SARS-CoV-2.Type: ApplicationFiled: January 10, 2022Publication date: April 4, 2024Inventors: Nicholas KEEN, Gemma MUDD, Katerine VAN RIETSCHOTEN, Katie GAYNOR, Liuhong CHEN, Maximilian HARMAN, Michael SKYNNER, Paul BESWICK, Mehdi AMOURA, Simone GIORGI, Giulia LATTANZI, Iain LINGARD
-
Publication number: 20240091368Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders of ACE2. The invention also includes pharmaceutical compositions comprising said polypeptides and to the use of said polypeptides in suppressing or treating a disease or disorder mediated by ACE2, such as infection of COVID-19 or for providing prophylaxis to a subject at risk of infection of COVID-19.Type: ApplicationFiled: January 10, 2022Publication date: March 21, 2024Inventors: Nicholas KEEN, Katerine VAN RIETSCHOTEN, Liuhong CHEN, Maximilian HARMAN, Paul BESWICK, Paul BESWICK
-
Publication number: 20240083945Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the COVID-19 nucleocapsid protein (N-protein). The invention also includes pharmaceutical compositions comprising said polypeptides and to the use of said polypeptides in suppressing or treating a disease or disorder mediated by the COVID-19 nucleocapsid protein (N-protein), such as infection of COVID-19 or for providing prophylaxis to a subject at risk of infection of COVID-19.Type: ApplicationFiled: January 10, 2022Publication date: March 14, 2024Inventors: Nicholas KEEN, Liuhong CHEN, Maximilian HARMAN, Michael SKYNNER, Paul BESWICK, Yuliya DEMYDCHUK
-
Publication number: 20240083944Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), particularly the spike protein S1 of SARS-CoV-2. The invention also includes pharmaceutical compositions comprising said polypeptides and to the use of said polypeptides in suppressing or treating a disease or disorder mediated by infection of SARS-CoV-2 or for providing prophylaxis to a subject at risk of infection of SARS-CoV-2.Type: ApplicationFiled: January 10, 2022Publication date: March 14, 2024Inventors: Nicholas KEEN, Gemma MUDD, Katerine VAN RIETSCHOTEN, Katie GAYNOR, Liuhong CHEN, Maximilian HARMAN, Michael SKYNNER, Paul BESWICK, Mehdi AMOURA, Simone GIORGI, Giulia LATTANZI, Iain LINGARD
-
Patent number: 11912792Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.Type: GrantFiled: August 17, 2022Date of Patent: February 27, 2024Assignee: BicycleTx LimitedInventors: Paul Beswick, Liuhong Chen, Gemma Mudd, Peter Park, Katerine Van Rietschoten, Michael Rigby
-
Publication number: 20240018508Abstract: The present invention relates to a method for determining an extent of cyclisation of a peptide ligand displayed on a genetic display system, wherein the peptide ligand comprises a polypeptide covalently linked to a molecular scaffold at two or more amino acid residues, comprising the steps of exposing the polypeptide displayed on the genetic display system to the molecular scaffold, wherein said polypeptide comprises two or more peptide reactive groups on said two or more amino acid residues which form covalent bonds with the molecular scaffold at two or more scaffold reactive groups, to give the peptide ligand; removing unreacted molecular scaffold from the genetic display system; exposing the peptide ligand displayed on the genetic display system to a first probe, wherein the first probe binds to a first unconjugated reactive group on the peptide ligand; and measuring the first unconjugated reactive group on the peptide ligand.Type: ApplicationFiled: October 2, 2020Publication date: January 18, 2024Inventors: Michael SKYNNER, James COOKE, Emma CRAWLEY, Liuhong CHEN, Gemma MUDD, Paul BESWICK
-
Publication number: 20230287047Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.Type: ApplicationFiled: August 17, 2022Publication date: September 14, 2023Inventors: Paul BESWICK, Liuhong CHEN, Gemma MUDD, Peter PARK, Katerine VAN RIETSCHOTEN, Michael RIGBY
-
Publication number: 20230183291Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of ACE2. The invention also includes pharmaceutical compositions comprising said polypeptides and to the use of said polypeptides in suppressing or treating a disease or disorder mediated by ACE2, such as infection of COVID-19 or for providing prophylaxis to a subject at risk of infection of COVID-19.Type: ApplicationFiled: May 14, 2021Publication date: June 15, 2023Inventors: Nicholas KEEN, Katerine VAN RIETSCHOTEN, Liuhong CHEN, Maximilian HARMAN, Michael SKYNNER, Paul BESWICK, Yuliya DEMYDCHUK
-
Publication number: 20230106511Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of penicillin-binding proteins (PBPs) more particularly PBP3. The invention also includes pharmaceutical compositions comprising said peptide ligands and to the use of said peptide ligands in suppressing or treating a disease or disorder mediated by bacterial infection or for providing prophylaxis to a subject at risk of infection.Type: ApplicationFiled: February 26, 2021Publication date: April 6, 2023Inventors: Matthew BALMFORTH, Paul BESWICK, Liuhong CHEN, Mike DAWSON, Rachel DODS, Catherine ROWLAND, Michael SKYNNER, Katerine VAN RIETSCHOTEN
-
Publication number: 20230086865Abstract: The present invention relates to a polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the bicyclic peptides of the invention are conjugated to a carrier peptide in order to greatly enhance the bacterial cell killing activity. More particularly, the invention describes peptides which are high affinity binders of penicillin-binding proteins (PBPs), such as PBP3 and PBP3a. The invention also includes pharmaceutical compositions comprising said conjugates and to the use of said conjugates in suppressing or treating a disease or disorder mediated by bacterial infection or for providing prophylaxis to a subject at risk of infection.Type: ApplicationFiled: February 26, 2021Publication date: March 23, 2023Inventors: Matthew BALMFORD, Paul BESWICK, Mike DAWSON, Rachel DODS, Catherine ROWLAND, Michael SKYNNER, Katerine VANRIETSCHOTEN, James WAGSTAFF
-
Publication number: 20230039677Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of IL-17. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by IL-17.Type: ApplicationFiled: December 16, 2020Publication date: February 9, 2023Inventors: Paul BESWICK, Gemma MUDD
-
Publication number: 20230041661Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of IL-17. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by IL-17.Type: ApplicationFiled: December 16, 2020Publication date: February 9, 2023Inventors: Paul BESWICK, Gemma MUDD
-
Publication number: 20230033370Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of IL-17. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by IL-17.Type: ApplicationFiled: December 16, 2020Publication date: February 2, 2023Inventors: Paul BESWICK, Gemma MUDD
-
Publication number: 20230021419Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of IL-17. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by IL-17.Type: ApplicationFiled: December 16, 2020Publication date: January 26, 2023Inventors: Paul BESWICK, Gemma MUDD
-
Publication number: 20230000847Abstract: The invention provides compounds of the formula (I): (I) wherein A1, A2, R2, R4, B1, B2, X, X1, n, a and b are as defined are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.Type: ApplicationFiled: March 4, 2022Publication date: January 5, 2023Inventors: Simon WARD, Paul BESWICK, Lewis PENNICOTT, Tristan REUILLON, Irina CHUCKOWREE, Carolina VILLALONGA-BARBER, Roderick Alan PORTER
-
Patent number: 11453702Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.Type: GrantFiled: September 30, 2021Date of Patent: September 27, 2022Assignee: BICYCLETX LIMITEDInventors: Paul Beswick, Liuhong Chen, Gemma Mudd, Peter Park, Katerine Van Rietschoten, Michael Rigby
-
Publication number: 20220281918Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of penicillin-binding proteins (PBPs). The invention also includes pharmaceutical compositions comprising said peptide ligands and to the use of said peptide ligands in suppressing or treating a disease or disorder mediated by bacterial infection or for providing prophylaxis to a subject at risk of infection.Type: ApplicationFiled: August 28, 2020Publication date: September 8, 2022Inventors: Katerine VAN RIETSCHOTEN, Paul BESWICK, Mike DAWSON, Matthew BALMFORTH, Michael SKYNNER, Liuhong CHEN
-
Patent number: 11396530Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.Type: GrantFiled: October 28, 2020Date of Patent: July 26, 2022Assignee: BICYCLETX LIMITEDInventors: Paul Beswick, Gemma Elizabeth Mudd, Kevin McDonnell, Gabriela Ivanova-Berndt, Katerine Van Rietschoten, David Witty, Michael Skynner
-
Patent number: 11298345Abstract: The invention provides compounds of the formula (I): (I) wherein A1, A2, R2, R4, B1, B2, X, X1, n, a and b are as defined are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.Type: GrantFiled: March 1, 2019Date of Patent: April 12, 2022Assignee: University College Cardiff Consultants LimitedInventors: Simon Ward, Paul Beswick, Lewis Pennicott, Tristan Reuillon, Irina Chuckowree, Carolina Villalonga-Barber, Roderick Alan Porter